AVS 1004
Alternative Names: AVS-1004Latest Information Update: 12 Dec 2023
Price :
$50 *
At a glance
- Originator Avelos Therapeutics
- Class Small molecules
- Mechanism of Action DNA damage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Nov 2023 Early research in Cancer in South Korea (unspecified route) (Avelos Therapeutics pipeline, November 2023)